Business Irish

Tuesday 24 January 2017

Bio-tech plastics maker rolls into €25m spend

Paul O'Donoghue

Published 27/04/2015 | 02:30

Cellulac recently signed a signed a five-year partnership deal with Dutch waste manager Pharmafilter worth €35m
Cellulac recently signed a signed a five-year partnership deal with Dutch waste manager Pharmafilter worth €35m

Irish biotechnology firm Cellulac is to invest €25m into redeveloping its plant in Dundalk in the second phase of a multi-year upgrade.

  • Go To

The company is leasing a 6.8-acre site from the Irish Whiskey Company. Cellulac is to retrofit the facility for the production of barrel plastics.

Speaking to the Irish Independent, Cellulac chief executive Gerry Brandon said that the company was set to begin phase one of the revamp in the first quarter of 2016, which he estimates will cost roughly €2m.

The second phase, set to commence in 2017, is estimated to cost €25m.

Mr Brandon said that the first phase will allow the firm to ramp up production at the facility initially to 20,000 tonnes a year of an acid used to produce biodegradable plastics for export.

He said that construction of the second phase was set to begin at the end of 2017 and run into 2018, and said that by the time it was completed the plant will be producing approximately 100,000 tonnes a year.

He added that the retrofit would add about 30 jobs to the firm, which employs 19 people.

He said: "Most jobs will be created in phase one, where there will be about 36 new jobs. During phase two there will probably be work for another 50 people in construction and then production in the plant will become automated, we will have just under 50 people working full-time."

He said that in total in equity and grants the firm has received roughly €16m so far.

He added that the company would look at its funding options within the next 12 months.

Cellulac recently signed a signed a five-year partnership deal with Dutch waste manager Pharmafilter worth €35m.

Irish Independent

Read More

Promoted articles

Editors Choice

Also in Business